Information  X 
Enter a valid email address

OptiBiotix Health (OPTI)

  Print      Mail a friend

Monday 16 March, 2020

OptiBiotix Health

Director's Dealing

RNS Number : 2832G
OptiBiotix Health PLC
16 March 2020
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Director's Dealing

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.

 

Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

Cairn Financial Advisers LLP (NOMAD)

 

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

 

finnCap (Broker)

 

Geoff Nash / Kate Bannatyne (Corporate Finance)

Camille Gochez (Corporate Broking)

 

Tel: 020 7220 0500

 

goetzpartner securities Limited

Ulrich Kinzel

 

Walbrook PR Ltd

 

 

Tel: 020 3859 7725

Anna Dunphy

Mob: 07876 741 001

     

 

 

About OptiBiotix - www.optibiotix.com  

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Frédéric AndréNarbel

2

Reason for notification

 

a.

Position/Status

Director of the Company

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

25,700 ordinary shares of 2p each
 

 

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of 25,700 ordinary shares in the Company

 

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

39.5p

38.4p

22,500

3,200

 

 

d.

Aggregated information

Volume

Price

 

25,700

39.37p

e.

Date of the transaction

12 March 2020

f.

Place of the transaction

London Stock Exchange, AIM

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFQLFFBXLZBBX

a d v e r t i s e m e n t